Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV vaccination and screening in young adult WLWH (H2VICTORY)
NCT05173324Phase 3Not yet recruiting
- Sponsor
- International Agency for Research on Cancer
- Start
- Feb 2023
- Primary completion
- Jun 2027
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, triple-blind trial of human papillomavirus vaccine in human papillomavirus infection (3 arms), sponsored by International Agency for Research on Cancer. Primary endpoint: HPV infection at 24 months. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
human papillomavirus vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05173324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05173324.